新型大环内酯类药物A-56268（TE-031）与红霉素和克林霉素相比，对所选革兰氏阳性菌和革兰氏阴性菌的体外活性。
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
作者信息
Benson C A, Segreti J, Beaudette F E, Hines D W, Goodman L J, Kaplan R L, Trenholme G M
出版信息
Antimicrob Agents Chemother. 1987 Feb;31(2):328-30. doi: 10.1128/AAC.31.2.328.
Abstract
The in vitro activity of A-56268 was determined and compared with that of erythromycin and clindamycin against a limited spectrum of 401 gram-positive and gram-negative organisms. A-56268 was quite active against erythromycin-susceptible Staphylococcus aureus, Neisseria gonorrhoeae, Listeria monocytogenes, Streptococcus pneumoniae, Streptococcus pyogenes, and group B streptococci and was moderately active against Campylobacter fetus subsp. fetus. A-56268 was consistently bactericidal only for S. pneumoniae. The activity of A-56268 was comparable to that of erythromycin against most organisms tested.
摘要
测定了A - 56268对401株革兰氏阳性和革兰氏阴性菌的体外活性，并将其与红霉素和克林霉素进行了比较。A - 56268对红霉素敏感的金黄色葡萄球菌、淋病奈瑟菌、单核细胞增生李斯特菌、肺炎链球菌、化脓性链球菌和B组链球菌有较强活性，对胎儿弯曲菌胎儿亚种有中等活性。A - 56268仅对肺炎链球菌始终具有杀菌作用。A - 56268对大多数测试菌株的活性与红霉素相当。
相似文献
1
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
Antimicrob Agents Chemother. 1987 Feb;31(2):328-30. doi: 10.1128/AAC.31.2.328.
2
Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria and Chlamydia trachomatis.
Eur J Clin Microbiol. 1987 Apr;6(2):173-8. doi: 10.1007/BF02018203.
3
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):30-3. doi: 10.1007/BF01969529.
4
CEM-101 activity against Gram-positive organisms.
Antimicrob Agents Chemother. 2010 May;54(5):2182-7. doi: 10.1128/AAC.01662-09. Epub 2010 Feb 22.
5
Comparative in-vitro activity of A-56268 (TE-031), a new macrolide antibiotic.
J Antimicrob Chemother. 1987 Nov;20(5):671-5. doi: 10.1093/jac/20.5.671.
6
In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
Clin Ther. 1993 Jan-Feb;15(1):107-13.
7
8
Inducible clindamycin resistance in β-hemolytic streptococci and Streptococcus pneumoniae.
Isr Med Assoc J. 2013 Jan;15(1):27-30.
9
Antibacterial activity of rokitamycin compared with that of other macrolides.
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):331-5. doi: 10.1016/0732-8893(91)90024-a.
10
Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3693-3697. doi: 10.1016/j.bmcl.2017.07.017. Epub 2017 Jul 5.
引用本文的文献
1
Choosing the right macrolide antibiotic. A guide to selection.
Drugs. 1997 Mar;53(3):349-57. doi: 10.2165/00003495-199753030-00002.
2
Clarithromycin clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003.
3
Antimicrobial susceptibility of coagulase-negative staphylococci.
Antimicrob Agents Chemother. 1994 Oct;38(10):2231-7. doi: 10.1128/AAC.38.10.2231.
4
New directions for macrolide antibiotics: structural modifications and in vitro activity.
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
5
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.
Antimicrob Agents Chemother. 1987 Dec;31(12):1939-47. doi: 10.1128/AAC.31.12.1939.
6
In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
Eur J Clin Microbiol Infect Dis. 1990 May;9(5):361-5. doi: 10.1007/BF01973747.
7
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388.
8
In vitro susceptibilities of aerotolerant Campylobacter isolates to 22 antimicrobial agents.
Antimicrob Agents Chemother. 1992 Apr;36(4):717-22. doi: 10.1128/AAC.36.4.717.
9
Comparative in vitro activity of clarithromycin. Spanish Collaborative Group.
Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):856-66. doi: 10.1007/BF01960892.
10
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Drugs. 1992 Jul;44(1):117-64. doi: 10.2165/00003495-199244010-00009.
本文引用的文献
1
Susceptibility of Legionella pneumophila to twenty antimicrobial agents.
Antimicrob Agents Chemother. 1980 Sep;18(3):403-8. doi: 10.1128/AAC.18.3.403.
2
Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.
Am J Med Sci. 1967 Jun;253(6):639-50. doi: 10.1097/00000441-196706000-00001.
3
Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species.
Antimicrob Agents Chemother. 1985 Mar;27(3):429-30. doi: 10.1128/AAC.27.3.429.
4
Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture.
Antimicrob Agents Chemother. 1977 Jul;12(1):80-3. doi: 10.1128/AAC.12.1.80.
5
Erythromycin: clinical review. II. Therapeutic uses.
N Y State J Med. 1977 Dec;77(14):2243-6.
6
Erythromycin: clinical review I. Clinical pharmacology.
N Y State J Med. 1977 Nov;77(13):2088-94.
Zotero 插件